Can fast-growing Eliquis overtake J&J's Xarelto? Bristol's execs think so

Eliquis, a new-age anticoagulant that once dragged well behind analysts' expectations, has seriously picked up the pace lately, rocketing to the top of Bristol-Myers Squibb's ($BMY) sales charts. And company execs don't expect it to stop there. As CEO Giovanni Caforio put it on last week's Q4 conference call, its recent performance puts the company "well on our way" to passing by a pair of hefty competitors in Johnson & Johnson ($JNJ) and Bayer's Xarelto and Boehringer Ingelheim's Pradaxa. More from FiercePharmaMarketing

Suggested Articles

With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections.

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.